Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cullinan Therapeutics

8.54
+0.26003.14%
Volume:344.01K
Turnover:2.87M
Market Cap:499.70M
PE:-2.74
High:8.58
Open:8.28
Low:8.07
Close:8.28
Loading ...

Cullinan Therapeutics to Initiate US Study of CLN-978 for Moderate to Severe Sjogren's Disease

MT Newswires Live
·
29 Apr

Cullinan Therapeutics to Initiate Study of Cln-978, a Bispecific Cd19 T Cell Engager Administered Subcutaneously, in Patients With SjÖGren’s Disease in the United States

THOMSON REUTERS
·
29 Apr

Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren’s Disease in the United States

GlobeNewswire
·
29 Apr

Cullinan Therapeutics to presents REZILIENT1 trial results at ASCO 2025

TIPRANKS
·
23 Apr

Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025

GlobeNewswire
·
23 Apr

Promising Potential of Cullinan Management’s CLN-978 in Rheumatoid Arthritis Treatment Justifies Buy Rating

TIPRANKS
·
17 Apr

Cullinan Therapeutics Says EU Regulator Clears Phase 1 Rheumatoid Arthritis Trial

MT Newswires Live
·
16 Apr

Cullinan Management’s Promising Pipeline and Market Potential Justify Buy Rating and $33 Price Target

TIPRANKS
·
16 Apr

BRIEF-Cullinan Therapeutics Receives Approval From European Medicines Agency To Initiate Phase 1 Trial Of Cln-978

Reuters
·
16 Apr

Cullinan Therapeutics Receives Approval From European Medicines Agency to Initiate Phase 1 Trial of Cln-978, a Bispecific Cd19 T Cell Engager Administered Subcutaneously, in Patients With Rheumatoid Arthritis

THOMSON REUTERS
·
16 Apr

Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis

GlobeNewswire
·
16 Apr

Cullinan Oncology Coverage Assumed by Morgan Stanley at Overweight

Dow Jones
·
08 Mar

Cullinan Therapeutics: Promising Pipeline and Upcoming Catalysts Justify Buy Rating

TIPRANKS
·
07 Mar

Cullinan Oncology Price Target Maintained With a $33.00/Share by HC Wainwright & Co.

Dow Jones
·
28 Feb

Cullinan Management Faces Uncertainty Amid Market Forecast Challenges and Competitive Pressures

TIPRANKS
·
28 Feb

Cullinan Therapeutics Reports 2024 Financial Results and Updates

TIPRANKS
·
28 Feb

Cullinan Management Executives Cash In on Stock Sales

TIPRANKS
·
28 Feb

Analysts Are Bullish on Top Healthcare Stocks: GH Research (GHRS), Cullinan Management (CGEM)

TIPRANKS
·
28 Feb

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NTLA) and Cullinan Management (CGEM)

TIPRANKS
·
28 Feb

Cullinan Therapeutics Q4 2024 GAAP EPS $(0.73) Beats $(0.76) Estimate

Benzinga
·
27 Feb